0
Article |

Change in Bone Mineral Density Among Adolescent Women Using and Discontinuing Depot Medroxyprogesterone Acetate Contraception FREE

Delia Scholes, PhD; Andrea Z. LaCroix, PhD; Laura E. Ichikawa, MS; William E. Barlow, PhD; Susan M. Ott, MD
[+] Author Affiliations

Author Affiliations: Center for Health Studies, Group Health Cooperative, Seattle, Wash (Drs Scholes, LaCroix, and Barlow and Ms Ichikawa); Departments of Epidemiology (Drs Scholes and LaCroix) and Biostatistics (Dr Barlow), School of Public Health and Community Medicine, Department of Medicine (Dr Ott), School of Medicine, University of Washington, Seattle; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle (Dr LaCroix); Cancer Research and Biostatistics, Seattle (Dr Barlow).


Arch Pediatr Adolesc Med. 2005;159(2):139-144. doi:10.1001/archpedi.159.2.139.
Text Size: A A A
Published online

Background  Several studies report an association between depot medroxyprogesterone acetate (DMPA) injectable contraception and decreased bone mineral density. Adolescents, who are still gaining bone, may be particularly affected, but there has been little study of the association in adolescent users and none following discontinuation.

Objective  To evaluate bone mineral density changes in adolescents using and discontinuing use of DMPA contraception.

Design  A population-based prospective cohort study.

Participants  One hundred seventy adolescent women, aged 14 to 18 years; 80 baseline DMPA users and 90 age-similar, unexposed comparison women. Sixty-one participants discontinued DMPA use during follow-up.

Main Outcome Measure  Bone mineral density, measured every 6 months for 24 to 36 months at the hip, spine, and whole body, comparing mean bone mineral density changes in DMPA users and discontinuers with nonusers.

Results  Among DMPA users, bone mineral density declined significantly relative to nonusers at the hip and spine but not the whole body. Annualized mean percentage changes, adjusted for covariates, were hip, –1.81% vs –0.19%; P<.001; spine, −0.97% vs 1.32%; P<.001, and whole body, 0.73% vs 0.88%; P = .78 for DMPA users vs nonusers, respectively. New users lost bone mineral density more rapidly than prevalent users. Discontinuers experienced significantly increased bone mineral density relative to nonusers at all anatomical sites; annualized mean percentage changes were hip, 1.34% vs –0.19%; P = .004; spine, 2.86% vs 1.32%; P = .004; and whole body, 3.56% vs 0.88%; P<.001.

Conclusions  Use of DMPA contraception in adolescents was associated with significant continuous losses of bone mineral density at the hip and spine. However, significant gains postdiscontinuation provide evidence that the loss of bone mass is apparently reversed.

Figures in this Article

Attainment of peak bone mass during adolescence and early adulthood has lifelong implications for fracture risk. A number of studies now provide evidence that use of the progestin-based injectable contraceptive depot medroxyprogesterone acetate (DMPA) (Depo-Provera; Pfizer US Pharmaceutical Group, New York, NY) may adversely affect bone mineral density (BMD).115 Depot medroxyprogesterone acetate is a popular contraceptive worldwide and is currently the only injectable contraceptive available in the United States. Adolescents disproportionately rely on this method, with 10% of US women aged 15 to 19 years using this method vs 3% of US women overall.16 Adolescents are also still attaining peak BMD and thus may be particularly vulnerable to any hormonal effects on BMD accompanying this method.17,18

Relatively few studies have focused on the possible effects of DMPA on BMD in adolescent users. One study reported decreased spine BMD in DMPA users relative to controls.3 Our earlier evaluation of a reproductive-age cohort found that the youngest age group (aged 18-21 years) had the greatest BMD difference from age-similar comparison women at baseline10 but also showed the greatest gains after DMPA use was discontinued.14 To our knowledge, there has been no evaluation of changes in BMD in younger teen users after DMPA discontinuation.

We report the results of a 3-year pros-pective study of changes in BMD during DMPA use and after discontinuation in a population-based cohort of 170 adolescent women, aged 14 to 18 years at enrollment.

STUDY PARTICIPANTS

This study was conducted at Group Health Cooperative, a mixed-model managed health care system located in Seattle, Wash, with approximately 15 000 enrollees aged 14 to 18 years. All study procedures were reviewed and approved by the Group Health Human Subjects Committee. We obtained written informed consent from participants (or from parents, with assent from minors).

The study sampling and recruitment methods are detailed in an earlier report.19 Briefly, recruitment occurred from June 1999 to December 2000. Potential participants were selected from a population-based sampling frame derived from the health plan’s computerized data files. We selected monthly samples that included all 14- to 18-year-old women who were receiving DMPA injections and a random sample of age-similar comparison women who were not using DMPA.

Once selected, participants who were aged 18 years were contacted directly via letter and subsequent telephone recruitment. If potential participants were younger than 18 years, we sent a letter to the parent(s) describing the study and inviting their daughter’s participation. Although use of hormonal contraception was noted as 1 factor of interest, the contraceptive status of potential participants was not included in order to protect confidentiality. Subsequently, study staff telephoned parents to discuss the study, and if we received permission and the teen was interested, we spoke directly to the potential participant.

We excluded potential participants who were pregnant, lactating, or planning to become pregnant; who were using DMPA for noncontraceptive indications; or who had any conditions or medication use known to affect BMD. We also excluded potential comparison women who were premenarcheal or who reported previous DMPA use.

Following their baseline enrollment visit, study participants were asked to make follow-up clinic visits every 6 months. The study design incorporated a minimum of 24 months’ follow-up on all participants but allowed up to 36 months of follow-up for participants who entered the study early in the recruitment period.

We originally enrolled 174 participants, 81 of whom were using DMPA contraception and 93 who were not.19 During evaluation of the more detailed data from follow-up, 4 were found to be ineligible and were excluded (1 DMPA-exposed participant with prior steroid use and 3 comparison participants with prior DMPA use). Thus, the final study group consisted of 80 women using DMPA contraception and 90 nonusing, unexposed women. At 6, 12, 18, and 24 months, we completed follow-up visits for 90%, 84%, 82%, and 78% of the cohort, respectively. Less than 24 months of follow-up data were obtained for 34 women, principally because of being unable to contact the participant (n = 11) or the participant becoming pregnant or seeking pregnancy (n = 10). Additional 30- and 36-month visits were obtained from 110 and 77 participants, respectively. Ninety-one percent of participants made at least 2 follow-up visits.

DATA COLLECTION

At baseline and follow-up visits, participants completed questionnaires covering health history, contraception, pregnancy history, smoking, physical activity, caffeine intake, alcohol use, and demographics; a food frequency questionnaire of dietary consumption in the past 30 days20; height and weight measurements; and BMD measurements of the hip, spine, and whole body. We assessed BMD using dual-energy x-ray absorptiometry. Initially, we used a Hologic QDR 4500 (Hologic, Waltham, Mass) at clinic 1 and a Hologic QDR 2000 at clinic 2. In May 2002, clinic 1 upgraded to a Hologic Delphi model and the QDR 4500 was moved to clinic 2. We evaluated the possible shift in in vivo BMD readings in a volunteer sample of 20 women at each clinic site who were measured on both the original and replacement machines. The standard errors of the estimate for the linear regression equations (root mean square residual) were 0.013 to 0.022 g/cm2, which are similar to those reported in the literature21 and to our own precision studies.14 Based on these cross-calibration assessments, each BMD measurement after the densitometer change was adjusted using a linear regression model for each woman’s values at each anatomical site, standardizing to the original machine.

STATISTICAL ANALYSES

The primary study outcome was change in BMD for the hip, spine, and whole body for continuous DMPA use and DMPA discontinuation relative to nonuse. Analyses required that participants make at least 2 study visits to contribute BMD-change data to a given exposure category. We evaluated BMD change in 2 ways: (1) Using a general linear regression model, we evaluated adjusted mean percentage change from baseline at 12, 18, and 24 months. 2) We examined adjusted mean change in BMD (in grams per centimeter squared) for each 6-month interval in the 3 exposure groups using a marginal generalized estimating equations approach. This included additional comparison of BMD change with varying cumulative duration of exposure. These repeated measures models used all available data and accounted for differential follow-up and participants’ changing exposure status during the course of the study. The exposure of interest, DMPA use, was entered as a time-dependent covariate, and each participant was classified as to her status at the beginning of every 6-month interval. Women who missed a visit reentered analyses at the next visit they completed. An independent working correlation structure was assumed since both time-dependent and fixed baseline covariates were included. Covariates that were associated with either BMD or DMPA exposure were evaluated for inclusion in the models either to increase precision or to control for possible confounding. Analyses were adjusted for baseline covariates (BMD, ethnicity [white], prior pregnancy, age at menarche) and time-dependent covariates (age, smoking status, calcium intake, and percentage body fat). For participants wearing nonremovable navel jewelry, the underlying vertebral BMD was calculated using the z scores from the uninvolved vertebrae.

We also calculated an estimated volumetric BMD (in grams per centimeter cubed) for the spine, since during periods of growth, the volume at the spine increases at a faster rate than the area. Thus, the areal density (in grams per centimeter squared) as measured by dual-energy x-ray absorptiometry will increase with bone growth even when the volumetric BMD remains unchanged. For each vertebra, the volumetric BMD was calculated as the areal BMD divided by the square root of the area. The overall volumetric BMD was the average of the volumetric BMDs of the 4 lumbar vertebrae.22

STUDY SAMPLE

Baseline characteristics of the cohort, by DMPA exposure status, are shown in Table 1. Thirty percent of participants were 16 years or younger, and 30% were nonwhite. The DMPA-exposed teens were significantly more likely than DMPA-unexposed participants to currently smoke, have been pregnant, and have navel jewelry, an earlier age at menarche, lower calcium intake, and higher body mass index, body fat, and percentage body fat.

Table Graphic Jump LocationTable 1. Participant Characteristics at Baseline by DMPA Exposure Status*

All women using DMPA were receiving the standard contraceptive dose (150 mg every 3 months). At baseline, DMPA use ranged from 1 to 13 injections (approximately 1-39 months). About 30% of the group had received only 1 injection (defined as new users), 31% had received 2 to 3 injections, 21% had 4 to 7, and 18% had 8 or more (Table 1). Median duration of use among prevalent users at baseline was 4 injections (approximately 12 months). Among the 90 women in the comparison group, 19% reported oral contraceptive use at baseline. This group had lower baseline BMD than other comparison women (data not shown). However, as these differences were not significant for any anatomical site, the entire DMPA-unexposed group comprised the comparator.

Baseline BMD was lower at all anatomical sites for DMPA-exposed as compared with unexposed participants, but differences were not statistically significant (Table 1).22 Of the teens who were receiving DMPA injections, 61 (71%) discontinued DMPA injections at some point during follow-up; 21% discontinued within the first 6 months of enrollment. Following discontinuation, we were able to follow up participants for a mean of 14 months (range, 0.4 to 36.0 months). The range of DMPA use prior to discontinuation was 3 to 62 months (60 of 61 discontinuers had at least 2 injections at discontinuation). In the comparison group, 6 participants initiated DMPA use and subsequently contributed time as new DMPA users.

CHANGES IN BMD WITH CONTINUOUS DMPA USE

For study participants who continued to use DMPA, mean BMD declined during follow-up at the hip and spine. Whole body BMD increased slightly (Figure) (Table 2). Among comparison women, there were small mean BMD decreases at the hip, with increased BMD at the spine and whole body.

Place holder to copy figure label and caption
Figure.

Mean percentage change in bone mineral density (BMD) from baseline by depot medroxyprogesterone acetate (DMPA) exposure status, adjusted for baseline covariates (BMD, ethnicity, pregnancy, age at menarche) and time-dependent covariates (age, smoking status, calcium intake, percentage body fat). Error bars represent 1 SE from the mean. New users (n = 17, 9, and 8 at 12, 18, and 24 months, respectively) received 1 DMPA injection; prevalent users (n = 26, 18, and 14 at 12, 18, and 24 months, respectively) received more than 1 DMPA injection. For DMPA discontinuers (n = 26, 14, and 5 at 12, 18, and 24 months, respectively), the intervals refer to the length of time participants were followed up after becoming discontinuers. The number of nonusers at 12, 18, and 24 months was 69, 69, and 59, respectively. A, Total hip BMD. B, Spine BMD. C, Whole body BMD.

Graphic Jump Location
Table Graphic Jump LocationTable 2. Multivariable Repeated Measures Model: Mean BMD Change per 6-Month Interval by DMPA Exposure Status*

After adjusting for baseline and time-dependent covariates, the mean percentage change in BMD from baseline (at 12-, 18-, and 24-month follow-ups) differed significantly for the hip and spine for DMPA users relative to comparison women (Figure). Changes at these 2 sites were greater for new users of this method than for prevalent users; for example, after 24 months, new users showed a –6.09% change at the hip while change for prevalent users was –2.04%. Change for nonusers was –0.92%.

Results were similar in the repeated measures models, which evaluated mean BMD change, in grams per centimeter squared, at 6-month intervals (Table 2). Adjusted BMD change at the hip was −0.0088 g/cm2 for continuous DMPA users compared with –0.0010 g/cm2 in nonusers for each 6-month interval; at the spine, the adjusted mean change was −0.0050 vs 0.0062 g/cm2 for users and nonusers, respectively; and at whole body adjusted mean change was 0.0039 vs 0.0046 g/cm2, respectively. Differences between users and nonusers were significant at the hip and spine (P<.001 at hip and spine; P = .78 for whole body). Based on these models, the calculated annualized mean percentage change in BMD among DMPA continuous users, after adjustment, was –1.81%, −0.97%, and 0.73% at the hip, spine, and whole body, respectively, compared with –0.19%, 1.32%, and 0.88% for comparison women.

In evaluating BMD change with varying cumulative durations of use, the adjusted mean change in BMD for each 6-month interval decreased with increasing DMPA cumulative use (P value for grouped linear trend = .003, .004, and.07 for the hip, spine, and whole body, respectively) (data not shown). Change was greatest for those with the least cumulative use, but DMPA users continued to lose BMD at the hip and spine well beyond 24 months of use.

Changes in the volumetric BMD at the spine (in grams per centimeter cubed) were smaller, but differences between DMPA users and nonusers continued to be highly significant (P<.001) (data not shown).

CHANGES IN BMD FOLLOWING DISCONTINUATION DMPA USE

The 61 participants who discontinued DMPA use at some time during the study had bone loss patterns during DMPA use that were similar to participants who continued use. After discontinuation, BMD increased.

Eighteen months postdiscontinuation, the adjusted mean percentage changes from baseline were significantly higher for DMPA discontinuers than for nonusers at all anatomical sites (P = .005, .023, and.001 at the hip, spine, and whole body for discontinuers compared with nonusers), with the greatest changes occurring at the whole body (Figure).

In our examination of changes in BMD (in grams per centimeter squared), the adjusted mean gains among DMPA discontinuers for each 6-month interval were 0.0058, 0.0133, and 0.0186 g/cm2 for the hip, spine, and whole body, respectively; for nonusers, changes were –0.0010, 0.0062, and 0.0046 g/cm2 (Table 2). The annualized adjusted mean percentage change in BMD was 1.34%, 2.86%, and 3.56% for the hip, spine, and whole body for DMPA discontinuers compared with –0.19%, 1.32%, and 0.88% for nonusers. Differences between DMPA discontinuers and nonusers were statistically significant at all anatomical sites (P = .004, .004, and <.001 for the hip, spine, and whole body, respectively).

Women who discontinued DMPA use gained BMD during all of the available follow-up time, and we noted no differences in gain by the duration of DMPA use at discontinuation (data not shown). Adjusted mean BMD values for discontinuers were at least as high as those of nonusers for all anatomical sites at 12 months and at all subsequent follow-up intervals.

Gains in volumetric BMD at the spine were also significant for discontinuers relative to nonusers (P<.05) (data not shown).

There is increasing evidence that DMPA use may adversely affect skeletal health, plausibly because of the estrogen depletion accompanying use of this progestin-based agent.23,24 The DMPA-associated changes may be particularly important for adolescent women, who are in the process of attaining peak bone mass. This prospective evaluation in a cohort of adolescents addressed the related questions of BMD changes that accompany both DMPA use and DMPA discontinuation.

DOES BMD DECREASE DURING DMPA USE?

In this group of teens, those who continued use of DMPA experienced continuous and significant declines in adjusted BMD at both the hip and spine relative to comparison women. Our findings accord with those of other longitudinal studies of this association in older premenopausal women.2,5,12,14,15,25 A clinic-based study of adolescents by Cromer et al3 (15 new DMPA users and 17 controls; mean age, 15.5 years) also noted 12-month spine BMD losses similar in magnitude to those seen in the 24 new DMPA users in this study. Our inclusion of prevalent users allowed us to document that changes in BMD were greatest during the first 1 to 2 years of use but continued beyond this time frame; our range of DMPA exposure extended from 1 to 24 injections (approximately 1 to 72 months) by the study’s conclusion. We also observed similar between-group differences at multiple anatomical sites. In comparing these results with our recent cohort study among reproductive-age women from this same defined population,14 annualized mean percentage change was slightly higher at the hip and spine in the adolescents.

If not reversed, changes of the magnitude reported here could, potentially, have clinical consequences. Prospective studies relating BMD to the risk of fractures in postmenopausal women26 have shown that each standard deviation decrease in BMD approximately doubles the risk of fracture. The limited data available indicate that this relationship may apply to younger women as well.27 The population standard deviation for white women is about 13%.28 In our data, BMD at the hip decreased approximately 0.05 g/cm2 after 24 months, about 5% loss.

IS BMD REGAINED FOLLOWING DMPA DISCONTINUATION?

Given the efficacy and acceptability of this method and the growing evidence of DMPA-associated BMD losses, it is of great interest to know if any effects on BMD are reversible. Our findings suggest that, on discontinuation, BMD begins to undergo rapid recovery, particularly at the spine and whole body (Table 2). The process of recovery may be somewhat slower at the hip. To our knowledge, no other studies have evaluated bone recovery following DMPA discontinuation specifically in adolescents. However, our results generally accord with those reported for older premenopausal women2 and for our reproductive-age cohort.14 In the current study, mean annualized gains following discontinuation were greater than those seen in our reproductive-age cohort (1.34% vs 1.04% per year for the hip, and 2.86% vs 1.41% for the spine).

The increases in BMD after DMPA discontinuation show similarities to BMD changes after normal lactation, which appears to exert substantial but largely transient effects on BMD.2931 It would be difficult to determine whether DMPA-exposed women achieved the BMD that they would have in the absence of DMPA use. We did find, however, that adjusted mean BMD values for women 12 months or more after discontinuation were at least as high as those of comparison women at all of the anatomical sites.

In evaluating the possible association between DMPA and BMD, this study offers a number of strengths. To our knowledge, this is the most sizeable study to date in adolescents and the first population-based study, and it is the only evaluation of BMD changes following discontinuation of DMPA use. By using a prospective cohort design that enrolled both new and prevalent users of DMPA, we were able to evaluate durations of exposure well beyond the study’s follow-up length to assess both short- and long-term changes (a range of 1-24 injections by the end of the study). Of particular importance, we could assess BMD changes following DMPA cessation after short- and long-term use. We also used a population-based sampling strategy. This allowed us to enroll exposed and unexposed participants from the same defined population, minimizing comparability issues. We evaluated the consistency of our results by measuring BMD at multiple anatomical sites and by calculating volumetric BMD in this group of growing teens. Finally, we measured and controlled for the potentially confounding roles of numerous covariates of interest.

The main limitation of these data was attrition to the cohort, due primarily to the need to censor participants who became pregnant or began seeking pregnancy. We evaluated our BMD change in a number of ways, and in the repeated measures models of BMD change, we included all available data from each participant. Our study design also did not allow for assessment of BMD prior to DMPA exposure. However, in the 30% of exposed participants who had received only 1 injection at baseline, mean BMD very closely approximated that of unexposed comparison women at all anatomical sites.

Given the increasing public health importance of osteoporosis,32 factors that may affect peak bone mass attainment and maintenance have received deservedly greater emphasis. This study provides evidence that DMPA use by adolescents adversely impacts BMD at key anatomical sites. However, these results in teens and those from our previous cohort provide reassurance that bone loss is regained, even in younger users.

Correspondence: Delia Scholes, PhD, Center for Health Studies, Group Health Cooperative, 1730 Minor Ave, 16th Floor, Seattle, WA 98101 (scholes.d@ghc.org).

Accepted for Publication: October 12, 2004.

Funding/Support: This study was supported by grant R01 HD31165-08 from the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md (Dr Scholes).

Acknowledgment: We thank our study participants and Barbara Monsey, MPH, for overall project coordination, Jane Grafton, BA, for programming assistance, Cathy Hutchison, BS, for participant recruitment and retention activities, Mildred Magner, MA, for data management, and Holly Roberts, MA, for bone mineral density measurement and data collection.

Cundy  TEvans  MRoberts  HWattie  DAmes  RReid  IR Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991;30313- 16
PubMed
Cundy  TReid  IR Depot medroxyprogesterone and bone density. BMJ 1994;3081567- 1568
PubMed
Cromer  BABlair  JMMahan  JDZibners  LNaumovski  Z A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129671- 676
PubMed
Taneepanichskul  SIntaraprasert  STheppisai  UChaturachinda  K Bone mineral density during long term depot medroxyprogesterone acetate acceptors. Contraception 1997;561- 3
PubMed
Cundy  TCornish  JRoberts  HElder  HReid  IR Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998;92569- 573
PubMed
Paiva  LCPinto-Neto  AMFaundes  A Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 1998;58351- 355
PubMed
Gbolade  BEllis  SMurby  BRandall  SKirkman  R Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998;105790- 794
PubMed
Tang  OSTang  GYip  PLi  BFan  S Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception 1999;5925- 29
PubMed
Bahamondes  LPerrotti  MCastro  SFaundes  DPetta  CBedone  A Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 1999;71849- 852
PubMed
Scholes  DLaCroix  AZOtt  SMIchikawa  LEBarlow  WE Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 1999;93233- 238
PubMed
Petitti  DBPiaggio  GMehta  SCravioto  MCMeirik  O Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population: the WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000;95736- 744
PubMed
Berenson  ABRadecki  CMGrady  JJRickert  VIThomas  A A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001;98576- 582
PubMed
Wanichsetakul  PKamudhamas  AWatanaruangkovit  PSiripakarn  YVisutakul  P Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002;65407- 410
PubMed
Scholes  DLaCroix  AZOtt  SMIchikawa  LEBarlow  WE Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;13581- 587
PubMed
Berenson  ABRadecki Breitkopf  CGrady  JJRickert  VIThomas  A Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004;103899- 906
PubMed
Piccinino  LJMosher  WD Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998;304- 10
PubMed
Bachrach  LK Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001;1222- 28
PubMed
Bachrach  LKCundy  TOtt  SM Depot medroxyprogesterone acetate in teens: a risk for bone health? Pediatrics 2000;1061137- 1138
PubMed
Scholes  DLaCroix  AZIchikawa  LEBarlow  WEOtt  SM The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 2004;6999- 104
PubMed
Kristal  ARFeng  ZCoates  RJOberman  AGeorge  V Associations of race/ethnicity, education, and dietary intervention with the validity and reliability of a food frequency questionnaire: the Women's Health Trial Feasibility Study in Minority Populations. Am J Epidemiol 1997;146856- 869
PubMed
Blake  GM Replacing DXA scanners: cross-calibration with phantoms may be misleading. Calcif Tissue Int 1996;591- 5
PubMed
Ott  SMO’Hanlan  MLipkin  EWNewell-Morris  L Evaluation of vertebral volumetric vs areal bone mineral density during growth. Bone 1997;20553- 556
PubMed
Mishell  DR  Jr Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996;41381- 390
PubMed
Cundy  TAmes  RHorne  A  et al.  A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003;8878- 81
PubMed
Naessen  TOlsson  SEGudmundson  J Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;5235- 39
PubMed
Marshall  DJohnell  OWedel  H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;3121254- 1259
PubMed
Lappe  JMStegman  MRRecker  RR The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 2001;1235- 42
PubMed
Looker  ACWahner  HWDunn  WL  et al.  Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8468- 489
PubMed
Sowers  MCorton  GShapiro  B  et al.  Changes in bone density with lactation. JAMA 1993;2693130- 3135
PubMed
Ott  SMLipkin  EWNewell-Morris  L Bone physiology during pregnancy and lactation in young macaques. J Bone Miner Res 1999;141779- 1788
PubMed
Chantry  CJAuinger  PByrd  RS Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 2004;158650- 656
PubMed
Melton  LJ  III Hip fractures: a worldwide problem today and tomorrow. Bone 1993;14 ((suppl 1)) S1- S8
PubMed

Figures

Place holder to copy figure label and caption
Figure.

Mean percentage change in bone mineral density (BMD) from baseline by depot medroxyprogesterone acetate (DMPA) exposure status, adjusted for baseline covariates (BMD, ethnicity, pregnancy, age at menarche) and time-dependent covariates (age, smoking status, calcium intake, percentage body fat). Error bars represent 1 SE from the mean. New users (n = 17, 9, and 8 at 12, 18, and 24 months, respectively) received 1 DMPA injection; prevalent users (n = 26, 18, and 14 at 12, 18, and 24 months, respectively) received more than 1 DMPA injection. For DMPA discontinuers (n = 26, 14, and 5 at 12, 18, and 24 months, respectively), the intervals refer to the length of time participants were followed up after becoming discontinuers. The number of nonusers at 12, 18, and 24 months was 69, 69, and 59, respectively. A, Total hip BMD. B, Spine BMD. C, Whole body BMD.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Participant Characteristics at Baseline by DMPA Exposure Status*
Table Graphic Jump LocationTable 2. Multivariable Repeated Measures Model: Mean BMD Change per 6-Month Interval by DMPA Exposure Status*

References

Cundy  TEvans  MRoberts  HWattie  DAmes  RReid  IR Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991;30313- 16
PubMed
Cundy  TReid  IR Depot medroxyprogesterone and bone density. BMJ 1994;3081567- 1568
PubMed
Cromer  BABlair  JMMahan  JDZibners  LNaumovski  Z A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996;129671- 676
PubMed
Taneepanichskul  SIntaraprasert  STheppisai  UChaturachinda  K Bone mineral density during long term depot medroxyprogesterone acetate acceptors. Contraception 1997;561- 3
PubMed
Cundy  TCornish  JRoberts  HElder  HReid  IR Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998;92569- 573
PubMed
Paiva  LCPinto-Neto  AMFaundes  A Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 1998;58351- 355
PubMed
Gbolade  BEllis  SMurby  BRandall  SKirkman  R Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998;105790- 794
PubMed
Tang  OSTang  GYip  PLi  BFan  S Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception 1999;5925- 29
PubMed
Bahamondes  LPerrotti  MCastro  SFaundes  DPetta  CBedone  A Forearm bone density in users of Depo-Provera as a contraceptive method. Fertil Steril 1999;71849- 852
PubMed
Scholes  DLaCroix  AZOtt  SMIchikawa  LEBarlow  WE Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 1999;93233- 238
PubMed
Petitti  DBPiaggio  GMehta  SCravioto  MCMeirik  O Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population: the WHO Study of Hormonal Contraception and Bone Health. Obstet Gynecol 2000;95736- 744
PubMed
Berenson  ABRadecki  CMGrady  JJRickert  VIThomas  A A prospective, controlled study of the effects of hormonal contraception on bone mineral density. Obstet Gynecol 2001;98576- 582
PubMed
Wanichsetakul  PKamudhamas  AWatanaruangkovit  PSiripakarn  YVisutakul  P Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception. Contraception 2002;65407- 410
PubMed
Scholes  DLaCroix  AZOtt  SMIchikawa  LEBarlow  WE Injectable hormone contraception and bone density: results from a prospective study. Epidemiology 2002;13581- 587
PubMed
Berenson  ABRadecki Breitkopf  CGrady  JJRickert  VIThomas  A Effects of hormonal contraception on bone mineral density after 24 months of use. Obstet Gynecol 2004;103899- 906
PubMed
Piccinino  LJMosher  WD Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998;304- 10
PubMed
Bachrach  LK Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001;1222- 28
PubMed
Bachrach  LKCundy  TOtt  SM Depot medroxyprogesterone acetate in teens: a risk for bone health? Pediatrics 2000;1061137- 1138
PubMed
Scholes  DLaCroix  AZIchikawa  LEBarlow  WEOtt  SM The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women. Contraception 2004;6999- 104
PubMed
Kristal  ARFeng  ZCoates  RJOberman  AGeorge  V Associations of race/ethnicity, education, and dietary intervention with the validity and reliability of a food frequency questionnaire: the Women's Health Trial Feasibility Study in Minority Populations. Am J Epidemiol 1997;146856- 869
PubMed
Blake  GM Replacing DXA scanners: cross-calibration with phantoms may be misleading. Calcif Tissue Int 1996;591- 5
PubMed
Ott  SMO’Hanlan  MLipkin  EWNewell-Morris  L Evaluation of vertebral volumetric vs areal bone mineral density during growth. Bone 1997;20553- 556
PubMed
Mishell  DR  Jr Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996;41381- 390
PubMed
Cundy  TAmes  RHorne  A  et al.  A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab 2003;8878- 81
PubMed
Naessen  TOlsson  SEGudmundson  J Differential effects on bone density of progestogen-only methods for contraception in premenopausal women. Contraception 1995;5235- 39
PubMed
Marshall  DJohnell  OWedel  H Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;3121254- 1259
PubMed
Lappe  JMStegman  MRRecker  RR The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporos Int 2001;1235- 42
PubMed
Looker  ACWahner  HWDunn  WL  et al.  Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8468- 489
PubMed
Sowers  MCorton  GShapiro  B  et al.  Changes in bone density with lactation. JAMA 1993;2693130- 3135
PubMed
Ott  SMLipkin  EWNewell-Morris  L Bone physiology during pregnancy and lactation in young macaques. J Bone Miner Res 1999;141779- 1788
PubMed
Chantry  CJAuinger  PByrd  RS Lactation among adolescent mothers and subsequent bone mineral density. Arch Pediatr Adolesc Med 2004;158650- 656
PubMed
Melton  LJ  III Hip fractures: a worldwide problem today and tomorrow. Bone 1993;14 ((suppl 1)) S1- S8
PubMed

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles